When it comes to EGFR and lung cancer, is a mutation good or bad? Dr. Joel Neal of Stanford University Medical Center explains why non-mutated genes are called “wild type.” February 2014.
Author: Editor
Prof David Cameron from The Edinburgh Cancer Research Centre is committed to identifying potential new approaches to treating and preventing breast cancer. We caught up with him at EBCC9 in Glasgow to find out what’s new for breast cancer patients. He tells us about ongoing research as well as some of the findings that were being presented at the congress.
A retrospective study of the effect of extending mammography to age 75 was performed in the Netherlands to use data emerging from the change of policy shifting age-based mammography to 75 in 1999. More early stage tumours were detected but just as many cases of late-stage disease were discovered as before, implying that screening had not eliminated them and was not yielding a benefit. Further analysis confirmed that the harmful effects of over-treatment in this age group were outweighing any potential benefits of cancer detection. Dr. Liefers concluded that age-based screening is failing these patients who should receive mammography on…
A detailed analysis of risk factors including genomic markers of women with breast cancer has revealed that three-year mammographic screening is insufficient for around half of all women who could be candidates for annual screening. This is good news for regions where annual screening is the norm as it suggests a potential saving by screening less frequently in one subgroup, but perhaps less welcome news in countries such as the UK where three-year screening is recommended.
A massive Oxford meta-analysis they have completed has shown that adjuvant radiotherapy gives absolute benefits in terms of progression-free and overall- survival in women with breast cancer who have one, two, or three involved axillary lymph nodes clarifying a long-held uncertainty. Up to now four or more nodes has been a status known to benefit from R/T, while node-zero did not confer any benefit from R/T. The effect is surprisingly large and is just as strong among women who received either chemotherapy or endocrine therapy extending considerably the application of adjuvant radiotherapy.
Dr Poortmans presented a late breaking abstract at a workshop on the regional control of breast cancer, along with speakers from Denmark, Canada and the UK. His abstract was on the updated results of his groups EORTC ROG and BCG phase III trial22922/10925 confirming the benefits of chest irradiation for patients with early breast cancer irrespective of their axillary nodal status. One of the key new points the data were presently able to confirm was that such regional radiotherapy extends life not only in chemotherapy-naïve patients, but also in those who have received extensive systemic therapy.
Dr. Mark Socinski is a Professor of Medicine, University of Pittsburgh School of Medicine. In this video, he answers common questions about the role of the PD-1 checkpoint pathway in normal immune function and tumor immune evasion.
7° Riunione Nazionale A.I.G. Associazione Italiana GIST Onlus Bologna, 29 marzo 2014
Gestione degli effetti collaterali delle terapie e delle complicanze post-chirurgiche 7 ° Riunione Nazionale AIG Associazione Italiana GIST Onlus Bologna, 29-03-2014
Stato dell’arte e ricerca clinica attuale (SECONDA PARTE) 7 ° Riunione Nazionale AIG Associazione Italiana GIST Onlus Bologna 29 marzo 2014
Il percorso della ricerca nei GIST in laboratorio. 7° Riunione Nazionale A.I.G. Associazione Italiana GIST Onlus Bologna, 29 marzo 2014
7° Riunione Nazionale A.I.G. Associazione Italiana GIST Onlus Bologna, 29 marzo 2014
Caso clinico 3: terapia con Regorafenib in terza linea di trattamento. 7° Riunione Nazionale A.I.G. Associazione Italiana GIST Onlus Bologna, 29 marzo 2014
7° Riunione Nazionale A.I.G. Associazione Italiana GIST Onlus Bologna, 29 marzo 2014
Don Sharpe talks to Terri Guidi, MBA of Oncology Management and Consulting about a real life case study of an analysis of oncology practice value to the hospital.
Don Sharpe sits down with Ted Okon the Executive Director of The Community Oncology Alliance and they talk about what’s impacting cancer care at the COA annual meeting.
Don Sharpe talks to Ricky Newton, CPA of Cancer Specialists of Tidewater about how to understand the business issue of quality cancer care. The interview was presented at COA annual meeting.
Don Sharpe talks to Dr. Jeff Vacirca, MD of North Shore Hematology and Oncology concerning the Effects of Sequestration to Community Oncologists.
Don Sharpe of OBR interviews Dr. Ira Klein, MD where he asks What is Gene Forward and Gene Backward?
Don Sharpe sits down with Dr. Brian Van Tine, MD PhD or Washington University to talk about Management and Treatment of Sarcoma.
Don Sharpe discusses the Payer Perspective on Molecular Testing with Dr. Micheal Kolodziej, MD from Aetna at the COA annual meeting.
Don Sharpe of OBR talks about the variances in genetic testing and how that may affect health care decisions with Dr. Lee Newcomer, MD of UnitedHealthCare.
Don Sharpe talks about Molecular Testing for Cancer from a Payer Perspective with Dr. Sundeep Reddy, MD (Caris Life Sciences) at the COA annual meeting.
Don Sharpe of OBR discusses the topic What’s Making Your Oncologist Sick? with Dr. Joseph Lynch, MD at the COA annual meeting.
Don Sharpe talks to Rebecca Bechhold, MD about Integrating Palliative Care and Oncology from the COA annual meeting in Orlando.
Don Sharpe of OBR discusses The Genetic Science Behind Heredity Colon Cancer Syndromes with Dr. Larry Geier, MD at the COA annual meeting.
Don Sharpe of OBR discusses The Medical Home past and future with Bo Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance.
Don Sharpe of OBR discusses how an oncology practice get’s started with The Medical Home model and the implemenation process with Carol Murtaugh, RN, OCN of Hematology & Oncology Consultants. Interview conducted at the annual COA meeting in Orlando, FL.
Don Sharpe of OBR discusses the progress for payers who are using The Medical Home model with Gordon Kuntz of ION Solutions at the annual COA meeting in Orlando, FL.
Don Sharpe of OBR talks to Dr. Daniel McKeller, MD of the Commission on Cancer about the report on The Medical Home. The interview was at COA annual meeting.
Don Sharpe talks to Stuart Genschaw, Exec. Dir. of Cancer & Hematology Centers of Western Michigan about innovation within oncology payment reforms from the COA annual meeting.
Don Sharpe asks the question Why are you embracing payment reform at The Center for Cancer and Blood Disorders to Barry Russon, CEO. Community Oncology Alliance annual meeting.
Don Sharpe discusses the success at Advanced Medical Specialties using Accountable Care Organization (ACO) with Dr. Leonard Kalman, MD from the annual COA meeting.
Don Sharpe talks to Dr. Barbara McAneny, MD from New Mexico Cancer Center about the CMMI Award and setting up The Medical Home at the COA meeting in Orlando.
Don Sharpe talks about the importance of cancer patient advocacy from the point of view of a medical oncologists Dr. Erin Dunbar, MD of Piedmont Healthcare.
Don Sharpe discusses Dr Erin Dunbar, MD or Piedmont Healthcare her presentation entitled “Good News from the Oncologist” at the COA annual meeting.
Don Sharpe of OBR talks to Dr. Lucio Gordon, MD of Florida Cancer Specialists about the role of IT, Electronic Medical Records, and Big Data in the future for oncology.
Don Sharpe talks to Angel Aslo, PharmD about the role of in house pharmacies within the community oncology setting.
Don Sharpe discusses with Ray Bailey, PharmD the role in which in house pharmacies play within oncology practices.
Don Sharpe of OBR discusses a surprise announcement from Dr. Siddhartha Mukherjee author and Pulitzer prize winner for The Emperor of All Maladies: A Biography of Cancer
Don Sharpe of OBR discusses molecular profiling with Dr. John Powderly of Carolina BioOncology Institute at COA.
Don Sharpe discusses with Ray Bailey, PharmD the role in which in house pharmacies play within oncology practices.
Don Sharpe of OBR discusses a surprise announcement from Dr. Siddhartha Mukherjee author and Pulitzer prize winner for The Emperor of All Maladies: A Biography of Cancer
Don Sharpe of OBR discusses molecular profiling with Dr. John Powderly of Carolina BioOncology Institute at COA.
Stato dell’arte e ricerca clinica attuale (PRIMA PARTE) 7 ° Riunione Nazionale AIG Associazione Italiana GIST Onlus Bologna 29 marzo 2014
7° Riunione Nazionale A.I.G. Associazione Italiana GIST Onlus Bologna 29 marzo 2014
Terapia Sunitinib: verso la personalizzazione della cura. 7° Riunione Annuale A.I.G. Associazione Italiana GIST Onlus, Bologna 29 marzo 2014
Dott. Paolo G. Casali, Responsabile SSD Oncologia Medica Tumori Mesenchimali dell’Adulto, Fondazione IRCCS Istituto Nazionale Tumori – Milano 7° Riunione Nazionale A.I.G. Associazione Italiana GIST Onlus Bologna 29 marzo 2014
Messaggio dell’Associazione e Introduzione ai lavori 7° Riunione Nazionale A.I.G. Associazione Italiana GIST Onlus Bologna 29 marzo 2014
Imatininb nella terapia pre-operatoria, adiuvante e di prima linea nel trattamento del GIST 7° Riunione Nazionale A.I.G. Associazione Italiana GIST Onlus Bologna, 29 marzo 2014